Literature DB >> 6823117

Response of metastatic breast cancer to tamoxifen withdrawal: report of a case.

W Stein, G N Hortobagyi, G R Blumenschein.   

Abstract

This case history describes a patient with metastatic breast cancer treated sequentially with diethylstilbestrol, drug withdrawal, tamoxifen, and drug withdrawal again. An objective response was observed in all four instances. Withdrawal responses to tamoxifen exist and should be kept in mind for selected patients.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6823117     DOI： 10.1002/jso.2930220112

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  6 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).

Authors:  A Oliver Sartor; Catherine M Tangen; Maha H A Hussain; Mario A Eisenberger; Minoti Parab; Joseph A Fontana; Robert A Chapman; Glenn M Mills; Derek Raghavan; E David Crawford
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

3.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

Review 4.  Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Animal models of breast cancer: their diversity and role in biomedical research.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer.

Authors:  Amit Agrawal; John F R Robertson; K L Cheung
Journal:  World J Surg Oncol       Date:  2011-09-09       Impact factor: 2.754
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.